Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
RMD 
ResMed Inc (RMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: RMD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -51.39% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 32.65B USD | Price to earnings Ratio 26.28 | 1Y Target Price 270.09 |
Price to earnings Ratio 26.28 | 1Y Target Price 270.09 | ||
Volume (30-day avg) 921065 | Beta 0.74 | 52 Weeks Range 170.64 - 262.46 | Updated Date 04/1/2025 |
52 Weeks Range 170.64 - 262.46 | Updated Date 04/1/2025 | ||
Dividends yield (FY) 0.95% | Basic EPS (TTM) 8.46 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 25.35% | Operating Margin (TTM) 32.54% |
Management Effectiveness
Return on Assets (TTM) 13.89% | Return on Equity (TTM) 25.65% |
Valuation
Trailing PE 26.28 | Forward PE 21.69 | Enterprise Value 32966306537 | Price to Sales(TTM) 6.63 |
Enterprise Value 32966306537 | Price to Sales(TTM) 6.63 | ||
Enterprise Value to Revenue 6.69 | Enterprise Value to EBITDA 19.33 | Shares Outstanding 146867008 | Shares Floating 145926964 |
Shares Outstanding 146867008 | Shares Floating 145926964 | ||
Percent Insiders 0.67 | Percent Institutions 62.84 |
Analyst Ratings
Rating 3.72 | Target Price 256.02 | Buy 3 | Strong Buy 6 |
Buy 3 | Strong Buy 6 | ||
Hold 8 | Sell - | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
ResMed Inc
Company Overview
History and Background
ResMed Inc. was founded in 1989 by Peter Farrell after he licensed a CPAP device design from Dr. Colin Sullivan. It has grown to become a leading global manufacturer of respiratory medical devices.
Core Business Areas
- Sleep and Respiratory Care: Develops, manufactures, and distributes a comprehensive range of devices and masks for the treatment of sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. This is the main driver of revenue.
- Software as a Service (SaaS): Provides cloud-based software solutions that enable healthcare providers to manage patient populations, track adherence, and improve outcomes. These solutions are provided by Brightree and MatrixCare that were acquired.
Leadership and Structure
ResMed is led by CEO Michael Farrell. The company has a typical corporate structure with functional departments such as R&D, Manufacturing, Marketing, and Sales.
Top Products and Market Share
Key Offerings
- AirSense 10 Series: A CPAP device for treating sleep apnea. ResMed is the market leader in CPAP devices, estimated market share is approximately 40%. Competitors include Philips (PHG) and Fisher & Paykel Healthcare (FSPKF).
- AirMini: A portable CPAP device. Captures a small part of CPAP sales due to portability factor, though no public data is available. Competitors include Philips (PHG) and Fisher & Paykel Healthcare (FSPKF).
- Astral Series: A ventilator for treating respiratory insufficiency. Ventilator sales are about 10% of total sales. Competitors include Philips (PHG) and Hamilton Medical.
- Brightree and MatrixCare Software: Provide cloud-based solutions for home medical equipment (HME) providers and skilled nursing facilities. Exact market share is difficult to determine but they are a large provider for home medical equipment (HME) and skilled nursing facilities. Competitors include WellSky and PointClickCare.
Market Dynamics
Industry Overview
The sleep apnea and respiratory care market is growing due to aging populations, increasing awareness of sleep disorders, and technological advancements in devices and therapies. The SaaS market for healthcare is also growing.
Positioning
ResMed is a market leader in sleep apnea devices and related accessories, recognized for its innovation, product quality, and global reach. They are improving their software offerings and integrating them into their hardware platform.
Total Addressable Market (TAM)
The global sleep apnea devices market is estimated at USD 4.77 billion in 2024 and is expected to grow to USD 6.44 billion by 2029. ResMed is well-positioned to capture a significant share of this expanding market. Also, the healthcare SaaS market is growing, which adds to the TAM.
Upturn SWOT Analysis
Strengths
- Market leadership in sleep apnea devices
- Strong brand reputation
- Global distribution network
- Innovative product portfolio
- Increasing adoption of digital health solutions
Weaknesses
- Dependence on reimbursement policies
- Exposure to product recalls
- Competition from lower-priced alternatives
- High R&D expenses
Opportunities
- Expanding into emerging markets
- Developing new therapies for respiratory diseases
- Acquiring complementary businesses
- Leveraging digital health technologies
- Growth in telemedicine
Threats
- Increased competition
- Changes in reimbursement policies
- Technological obsolescence
- Economic downturns
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- PHG
- FSPKF
Competitive Landscape
ResMed benefits from its established brand, innovative technology, and global reach. Philips is a significant competitor, but ResMed has been gaining market share recently due to Philips's product recall issues. Fisher & Paykel Healthcare is another notable competitor, specializing in humidification and respiratory support products. The competitive advantage of ResMed is it's software offering that is integrated into its hardware sales.
Major Acquisitions
Propeller Health
- Year: 2019
- Acquisition Price (USD millions): 225
- Strategic Rationale: Acquisition of Propeller Health, a digital health company specializing in connected inhalers, to expand ResMed's digital health offerings for respiratory diseases.
EVE Sleep
- Year: 2023
- Acquisition Price (USD millions): 19.3
- Strategic Rationale: EVE sleep is a European company, and this acquisition allowed Resmed to extend its sleep solutions offerings to a larger market
Growth Trajectory and Initiatives
Historical Growth: ResMed has experienced consistent revenue and earnings growth over the past decade, driven by strong demand for its products and services.
Future Projections: Analysts project continued growth for ResMed, driven by the aging population, increased awareness of sleep apnea, and expansion into new markets. Expected revenue growth is around 10% annually.
Recent Initiatives: Recent initiatives include expanding into new markets, developing new digital health solutions, and acquiring complementary businesses.
Summary
ResMed is a strong market leader in the sleep apnea device market with a solid financial performance and a track record of consistent growth. It benefits from strong brand recognition, innovative technology, and a global distribution network. However, it needs to navigate increasing competition, reimbursement challenges, and technological advancements to maintain its market position.
Similar Companies
DXCM
DexCom Inc
DXCM
DexCom Inc
PHG
Koninklijke Philips NV ADR
PHG
Koninklijke Philips NV ADR
VRTX
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Market Research Reports
- Company Website
Disclaimers:
The information provided is for informational purposes only and should not be considered as financial advice. Investment decisions should be based on your own research and due diligence. Market conditions and company performance can change, affecting the accuracy of this information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ResMed Inc
Exchange NYSE | Headquaters San Diego, CA, United States | ||
IPO Launch date 1995-06-02 | CEO & Chairman Mr. Michael J. Farrell BE, MBA, SM | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees - | Website https://www.resmed.com |
Full time employees - | Website https://www.resmed.com | ||
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.